



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Update on COVID-19 Vaccine Administration & Current Status Regarding Mpox

Imelda Garcia, MPH

Associate Commissioner

Laboratory & Infectious Disease Services Division

April 12, 2023

DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. COVID Information is subject to change.


April 12, 2023



TEXAS
Health and Human
Services


**Texas Department of State
Health Services**

COVID-19 Vaccine Update



Bivalent COVID-19 Vaccine Booster Doses Administered, Texas (4/6/2023)

Age Group	Population	Number of Bivalent Boosters
5-11 years	2,898,962	61,544 (2.1%)
12-17 years	2,472,553	97,634 (3.9%)
18-49 years	12,885,909	679,668 (5.3%)
50-64 years	4,975,933	717,947 (14.4%)
65+ years	3,734,229	1,100,351 (29.5%)
Total	26,967,586	2,657,144 (9.9%)



COVID-19 Vaccine Updates

- On March 13, 2023, the U.S. Food and Drug Administration (FDA) updated the letter of authorization for Janssen COVID-19 Vaccine to revise the scope of authorization related to the Vaccine Adverse Event Reporting System (VAERS) reporting requirements for vaccination providers to include myocarditis and pericarditis. This revision is included under the Warning section of the fact sheet.¹
- On March 14, 2023, the FDA authorized a change in Pfizer's COVID-19 vaccine eligibility for children ages 6 months through 4 years.
 - Children ages 6 months through 4 years who completed their 3-dose primary series with Pfizer's original (monovalent) COVID-19 vaccine are now eligible for an updated Pfizer booster. The links to the updated fact sheet is below.²
 - [Updated Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)
- Novavax COVID-19 vaccine is now available in a smaller pack size (5-dose vials)
 - No changes to the storage & handling
 - The link to the updated fact sheet is below.³

1. [Janssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers 03132023 \(fda.gov\)](#)

2. [Pfizer HCP FS 6m-4y Maroon 03142023 \(fda.gov\)](#)

3. [Novavax HCP Fact Sheet 03282023 \(fda.gov\)](#)



TEXAS

Health and Human Services

Texas Department of State
Health Services



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Future COVID-19 Vaccines

Future COVID-19 Vaccines

The Food and Drug Administration (FDA) advisory committee on Vaccine Related Biologics and Product (VRBPAC) met on January 26, 2023. They discussed 3 specific issues:

1. Harmonizing vaccine strain composition for primary series and booster doses - the composition of all vaccines administered currently would be a bivalent vaccine (original + Omicron BA.4/BA.5).
 - Anticipate decision from the FDA as early as this week.
2. Simplifying the immunization schedule for a multi-dose series in some population(s), but one dose (possibly annually) for many individuals.
 - Anticipate some simplification with the harmonization to only bivalent vaccine.
3. Future strain selection and vaccine composition.
 - As per the FDA, strain selection to be finalized by late May/Mid-June in preparation for the Fall vaccination roll-out.



TEXAS

Health and Human Services

Texas Department of State
Health Services

COVID-19 Vaccine Program Transition to Vaccines for Children (VFC) Program



TEXAS

Health and Human Services

Texas Department of State
Health Services


- When COVID-19 vaccines are commercialized and no longer available under the USG's National COVID-19 Response, VFC providers will be able to order the vaccines through the VFC program.
- The timeline for commercialization of COVID-19 vaccines in the US has not yet been finalized. Anticipated timeline is late Fall 2023.



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Mpox Update



Mpox Situation Report 4/6/2023

Surveillance



TEXAS

Health and Human Services

Texas Department of State
Health Services

Total Cases	Confirmed	Probable
2,943	1,144	1,799

As of 4/6/2023 9:00:41 AM

Cases by Public Health Region

	Confirmed	Probable	Total Cases	% of Total Cases
1	5	5	10	0.3%
2/3	588	674	1,262	42.9%
4/5N	6	7	13	0.4%
6/5S	393	623	1,016	34.5%
7	108	282	390	13.3%
8	25	188	213	7.2%
9/10	9	4	13	0.4%
11	9	13	22	0.7%
UNK	1	3	4	0.1%
Total	1,144	1,799	2,943	100.0%

Case Demographics



TEXAS

Health and Human Services

Texas Department of State
Health Services

Age Category	# of Cases	% of Cases
<18 Years	17	0.6%
18-29 Years	859	29.2%
30-39 Years	1223	41.6%
40-49 Years	553	18.8%
50-59 Years	244	8.3%
60+ Years	46	1.6%
Total	2,942	100%

Race	# of Cases	% of Cases
Hispanic	8119	27.8%
Asian	52	1.8%
Black	937	31.8%
White	655	22.3%
Other	224	7.6%
Unknown	255	8.7%
Total	2,942	100%

Sex	# of Cases	% of Cases
Male	2848	96.8%
Female	88	3.0%
Unknown	6	0.2%
Total	2,910	100%




TEXAS

Health and Human Services

Texas Department of State
Health Services


Monkeypox Cases by Investigation Start Date, Texas 2022-2023



As of 4/6/2023

As of 4/6/2023, a total of 29,367 People Vaccinated (48,108 Doses) with JYNNEOS (ImmTrac2 data) in Texas

JYNNEOS Doses Administered (Immtrac2) by Vaccination Date



JYNNEOS Administration (ImmTrac2) by PHR					Cases	
PHR	One Dose	People Fully Vaccinated	Total Doses Administered	%	Total Cases	%
1	150	110	260	0.5%	10	0.3%
2/3	8,235	4,969	13,216	27.5%	1,262	42.9%
4/5N	121	73	194	0.4%	13	0.4%
6/5S	10,845	7,287	18,140	37.7%	1,016	34.5%
7	5,960	3,610	9,575	19.9%	390	13.3%
8	1,917	1,282	3,203	6.7%	213	7.2%
9/10	602	324	926	1.9%	13	0.4%
11	1,037	803	1,840	3.8%	22	0.7%
Unknown	500	253	754	1.6%	4	0.1%
Total	29,367	18,711	48,108	100.0%	2,943	100.0%

As of April 6, 2023, there are **10,521 individuals overdue** (day 43) for their second dose of JYNNEOS to complete the primary series.

DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. COVID Information is subject to change.

April 12, 2023